Stewart Alistair B, Delves George H, Birch Brian R, Cooper Alan J, Lwaleed Bashir A
Department of Urology, Southampton University Hospitals NHS Trust, Southampton, UK.
Scand J Urol Nephrol. 2009;43(2):104-8. doi: 10.1080/00365590802502103.
Antiprostasome antibodies (APAs) have been identified in serum of patients with prostate cancer and have been proposed as a new marker for metastatic disease. This study reassesses the role of APAs as a prognostic indicator for prostate cancer.
Serum samples from healthy controls (n=7) and patients with prostate cancer (n=22) were assayed for APAs using an enzyme-linked immunosorbent assay.
APAs in varying amounts were present in healthy individuals as well as in men with prostate cancer. Higher levels were inversely and significantly associated with prostate-specific antigen (PSA). No significant relationships were noted between APA levels and other parameters such as age, time since diagnosis, metastatic status, Gleason histological score and hormonal treatment.
The presence of serum APA is unlikely to be a strong prognostic indictor for prostate cancer on an individual basis as false positives will occur. However, such immune reactions which may be associated with PSA in cancer patients are in any case of interest in both the biology of prostate cancer and male fertility. The source of prostasomal antigen may be of critical importance to the outcome of the assay. However, immune reactions to prostasomes may be of considerable interest and warrant continued investigation.
在前列腺癌患者血清中已鉴定出抗前列腺小体抗体（APAs），并被提议作为转移性疾病的一种新标志物。本研究重新评估APAs作为前列腺癌预后指标的作用。
使用酶联免疫吸附测定法检测来自健康对照者（n = 7）和前列腺癌患者（n = 22）的血清样本中的APAs。
健康个体以及前列腺癌男性患者体内均存在不同量的APAs。较高水平与前列腺特异性抗原（PSA）呈显著负相关。未发现APA水平与年龄、诊断后时间、转移状态、Gleason组织学评分和激素治疗等其他参数之间存在显著关系。
血清APA的存在不太可能作为个体前列腺癌的强有力预后指标，因为会出现假阳性。然而，这种可能与癌症患者体内PSA相关的免疫反应，无论如何在前列腺癌生物学和男性生育力方面都值得关注。前列腺小体抗原的来源可能对检测结果至关重要。然而，对前列腺小体的免疫反应可能相当有趣，值得继续研究。
